Wei Qian, Foyn Håvard, Landskron Johannes, Wang Shixiong, Rye Inga Hansine, Skånland Sigrid S, Russnes Hege Elisabeth Giercksky, Klaveness Jo, Ahmad Rafi, Taskén Kjetil
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway.
Norwegian Centre for Clinical Cancer Research, MATRIX, Division of Cancer Medicine, Oslo University Hospital, 0424 Oslo, Norway.
iScience. 2025 Jan 31;28(3):111931. doi: 10.1016/j.isci.2025.111931. eCollection 2025 Mar 21.
FoxP3 regulatory T cells (Tregs) are responsible for immune homeostasis by suppressing excessive anti-self-immunity. Tregs facilitate tumor growth by inhibiting anti-tumor immunity. Here, we explored the targeting of FoxP3 as a basis for new immunotherapies. In a high-throughput phenotypic screening of a drug repurposing library using human primary T cells, we identified quinacrine as a FoxP3 downregulator. searches based on the structure of quinacrine, testing of sub-libraries of analogs and validation identified a subset of 9-amino-acridines that selectively abrogated Treg suppressive functions. Mechanistically, these acridines interfered with the DNA-binding activity of FoxP3 and inhibited FoxP3-regulated downstream gene regulation. Release from Treg suppression by 9-amino-acridines increased anti-tumor immune responses both in cancer patient samples and in mice in a syngeneic tumor model. Our study highlights the feasibility of screening for small molecular inhibitors of FoxP3 as an approach to pursuing Treg-based immunotherapy.
叉头框蛋白3调节性T细胞(Tregs)通过抑制过度的自身免疫反应来维持免疫稳态。Tregs通过抑制抗肿瘤免疫促进肿瘤生长。在此,我们探索了以靶向FoxP3作为新免疫疗法的基础。在使用人原代T细胞对一个药物再利用文库进行的高通量表型筛选中,我们确定了喹吖因是一种FoxP3下调剂。基于喹吖因的结构进行搜索、对类似物子文库进行测试并验证,确定了一个9-氨基吖啶子集,其选择性地消除了Treg的抑制功能。从机制上讲,这些吖啶干扰了FoxP3的DNA结合活性,并抑制了FoxP3调节的下游基因调控。在癌症患者样本和同基因肿瘤模型的小鼠中,9-氨基吖啶解除Treg抑制后增强了抗肿瘤免疫反应。我们的研究强调了筛选FoxP3小分子抑制剂作为一种基于Treg的免疫治疗方法的可行性。